Skip to main content
Clinical Trials/NCT02072278
NCT02072278
Completed
Phase 1

Interventional, Randomised, Double-blind, Placebo-controlled, Active Comparator, Four-way Crossover Electroencephalography Study Investigating the Effects of Vortioxetine (Lu AA21004) in Healthy Male Subjects

H. Lundbeck A/S1 site in 1 country32 target enrollmentFebruary 2014

Overview

Phase
Phase 1
Intervention
Vortioxetine 10 mg
Conditions
Healthy Men
Sponsor
H. Lundbeck A/S
Enrollment
32
Locations
1
Primary Endpoint
Battery of EEG measurements
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

To explore a neurophysiological marker (electroencephalography) of cognitive effect of vortioxetine

Registry
clinicaltrials.gov
Start Date
February 2014
End Date
November 2014
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The subject has a normal resting EEG at screening visit
  • The subject is able to perform tasks with an auditory stimulus
  • The subject is not visually impaired - normal prescription glasses are accepted
  • The subject has a normal circadian rhythm, defined as a person who usually wakes between 6:00 and 9:00 a.m. and goes to sleep between 9:00 pm and midnight.

Exclusion Criteria

  • The subject has worked shifts, including night duty, or has travelled across \>3 time zones \<2 weeks prior to the first dose of IMP.
  • Other inclusion and exclusion criteria may apply.

Arms & Interventions

Vortioxetine 10 mg

encapsulated tablets; 3 daily doses in each treatment period; orally

Intervention: Vortioxetine 10 mg

Vortioxetine 20 mg

encapsulated tablets; 3 daily doses in each treatment period; orally

Intervention: Vortioxetine 20 mg

Escitalopram 15 mg

encapsulated tablets; 3 daily doses in each treatment period; orally

Intervention: Escitalopram 15 mg

Placebo

capsules; 3 daily doses in each treatment period; orally

Intervention: Placebo

Outcomes

Primary Outcomes

Battery of EEG measurements

Time Frame: The EEG task battery will be conducted on Days -1 and starting 6 hours post-dose on Days 1 and 3 of each treatment period.

* Peak amplitude and latency of P300 * AUC of qEEG power spectral bands delta, theta, alpha, beta and gamma * AUC of evoked gamma power spectral band * Peak amplitude and latency of N200 * Peak amplitude and latency of error related negativity * Peak amplitudes and latencies in the evoked responses during successful versus non-successful encoding in the verbal memory task between treatments

Study Sites (1)

Loading locations...

Similar Trials